Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23854774 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP1A2CYP3A4GAA | |
| SCHEMBL25322608 | 0.92 | MAPT (0.58) | ALDH1A1MAPTCYP1A2CYP3A4GAA | |
| SCHEMBL83732 | 0.86 | KDM1A (0.49) | ALDH1A1MAPTCYP1A2CYP3A4GAA | |
| SCHEMBL84176 | 0.86 | KDM1A (0.49) | ALDH1A1MAPTCYP1A2CYP3A4GAA | |
| SCHEMBL3312540 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDLMNAHIF1A | |
| SCHEMBL22804482 | 0.84 | BRD4 (0.46) | ALDH1A1MAPTCYP1A2CYP3A4GAA | |
| SCHEMBL1995415 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTHPGDLMNAHIF1A | |
| SCHEMBL9509660 | 0.84 | PROKR1 (0.60) | ALDH1A1MAPTHTTHPGDLMNA | |
| SCHEMBL3737773 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTHPGDLMNAHIF1A | |
| SCHEMBL4099888 | 0.84 | RAB9A (0.57) | ALDH1A1MAPTGAAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626891-A | Synthesis method of nilapanib key intermediate | 四川轻化工大学 | 2023-01-20 | — | — | CN | claimed |
| CN-110300587-B | Deuterated (S) -2- (4- (piperidin-3-yl) phenyl) -2H-indazole-7-carboxamide | 康姆芘法思催化剂股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115626891-A | Synthesis method of nilapanib key intermediate | 四川轻化工大学 | 2023-01-20 | — | — | CN | disclosed |
| US-11384062-B2 | Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide | COMBIPHOS CATALYSTS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-110156751-B | Novel method for preparing nilapanib and intermediate thereof | 江苏食品药品职业技术学院 | 2022-01-18 | — | — | CN | disclosed |
| EP-3606524-B1 | DEUTERATED (S)-2-(4-(PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE | COMBIPHOS CATALYSTS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210300895-A1 | DEUTERATED (S)-2-(4-(PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE | COMBIPHOS CATALYSTS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300895-A1 | DEUTERATED (S)-2-(4-(PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE | BRCA1, PARP3, PARP8 | ALDH1A1 874/4885MAPT 3874/4885CYP1A2 394/4885 |
| US-11384062-B2 | Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide | BRCA1, PARP3, PARP8 | ALDH1A1 874/4885MAPT 3874/4885CYP1A2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.